Pfizer Inc. (NYSE:PFE) Shares Sold by Sharp Financial Services LLC

Sharp Financial Services LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 33.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 13,300 shares of the biopharmaceutical company’s stock after selling 6,700 shares during the period. Sharp Financial Services LLC’s holdings in Pfizer were worth $353,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Kelleher Financial Advisors grew its position in shares of Pfizer by 3.2% during the fourth quarter. Kelleher Financial Advisors now owns 35,357 shares of the biopharmaceutical company’s stock worth $938,000 after buying an additional 1,088 shares in the last quarter. Viking Fund Management LLC lifted its stake in Pfizer by 11.6% during the fourth quarter. Viking Fund Management LLC now owns 384,000 shares of the biopharmaceutical company’s stock worth $10,188,000 after purchasing an additional 40,000 shares during the last quarter. MBM Wealth Consultants LLC lifted its stake in Pfizer by 8.5% during the fourth quarter. MBM Wealth Consultants LLC now owns 9,347 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 729 shares during the last quarter. Missouri Trust & Investment Co lifted its stake in Pfizer by 3.6% during the fourth quarter. Missouri Trust & Investment Co now owns 51,757 shares of the biopharmaceutical company’s stock worth $1,373,000 after purchasing an additional 1,801 shares during the last quarter. Finally, Bourgeon Capital Management LLC lifted its stake in Pfizer by 610.3% during the fourth quarter. Bourgeon Capital Management LLC now owns 418,658 shares of the biopharmaceutical company’s stock worth $11,107,000 after purchasing an additional 359,721 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $26.01 on Thursday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50 day simple moving average of $26.09 and a 200-day simple moving average of $27.97. The stock has a market capitalization of $147.40 billion, a PE ratio of 35.15, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.61%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 227.03%.

Analyst Ratings Changes

Several research firms recently weighed in on PFE. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.